Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00335478 · ClinicalTrials.gov registry record · Phase 2
Daptomycin in Treating Neutropenia and Fever in Patients With Cancer
A Phase 2 study, sponsored by OHSU Knight Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 54
- Enrollment target
NCT00335478 is a Phase 2 study that has completed, run by OHSU Knight Cancer Institute. The registered enrollment target is 54 participants.
The verdict
NCT00335478, a Phase 2 study, has completed, sponsored by OHSU Knight Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 54 participants
- Enrollment target
Study Summary
RATIONALE: Antibiotics, such as daptomycin, may control neutropenia, fever, and infection in patients with cancer. PURPOSE: This phase II trial is studying how well daptomycin works in treating neutropenia and fever in patients with cancer.
Interventions
- DRUG Daptomycin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2006-12 |
| Est. Completion | 2008-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00335478
The ClinicalTrials.gov registry entry for NCT00335478 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is OHSU Knight Cancer Institute, which has 211 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Daptomycin is the first listed.
NCT00335478 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00335478 about?
NCT00335478 is a clinical study titled "Daptomycin in Treating Neutropenia and Fever in Patients With Cancer". RATIONALE: Antibiotics, such as daptomycin, may control neutropenia, fever, and infection in patients with cancer. PURPOSE: This phase II trial is studying how well daptomycin works in treating neutropenia and fever in patients with cancer.
What is the current status of trial NCT00335478?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 54 participants. The study started on 2006-12. Estimated completion is 2008-10.
What interventions are being tested in trial NCT00335478?
The interventions under investigation include: Daptomycin (DRUG).
Who is sponsoring clinical trial NCT00335478?
This trial is sponsored by OHSU Knight Cancer Institute, which has 211 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.